111 studies found for:    hepatitis C | Gilead [Lead]
Show Display Options
Rank Status Study
1 Recruiting Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Condition: Hepatitis C
Intervention: Drug: Harvoni
2 Completed A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
Condition: Hepatitis C
Interventions: Drug: Single Ascending Dose Cohorts GS-9620;   Drug: Multiple Ascending Dose Cohorts GS-9620
3 Completed Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: Sofosbuvir;   Drug: GS-0938;   Drug: RBV;   Drug: Placebo to match sofosbuvir;   Drug: Placebo to match GS-0938
4 Active, not recruiting Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
Condition: Hepatitis C
Interventions: Drug: SOF;   Drug: REB
5 Completed GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885;   Drug: GS-9451;   Biological: peginterferon alfa-2a;   Drug: ribavirin tablet;   Drug: GS-9451 Placebo
6 Completed GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885;   Drug: GS-9451;   Drug: tegobuvir;   Drug: placebo to match tegobuvir;   Drug: placebo to match RBV;   Drug: Ribavirin
7 Completed Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C
Interventions: Drug: GS-9669 tablets;   Drug: Placebo to Match GS-9669 tablet
8 Approved for marketing Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
Condition: Post-transplant Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin;   Drug: Pegylated Interferon
9 Completed A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: Hepatitis C, Chronic
Interventions: Drug: Tegobuvir (GS-9190);   Drug: GS-9451;   Biological: Pegasys®;   Drug: Copegus®;   Drug: Tegobuvir placebo;   Drug: GS-9451 placebo
10 Enrolling by invitation A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
Condition: Hepatitis C Virus Infection
Intervention: Drug: Sofosbuvir
11 Recruiting Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea
Condition: Hepatitis C Virus
Intervention: Drug: LDV/SOF
12 Completed Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885 tablet;   Drug: GS-9451 tablet;   Biological: peginterferon alfa-2a;   Drug: ribavirin tablet
13 Recruiting Evaluate the Safety and Effectiveness of Sovaldi Treatment Regimens in Patients With Chronic Hepatitis C Virus (HCV) Infection in a Korean Real-World Setting
Condition: Hepatitis C Virus
Intervention: Drug: Sofosbuvir
14 Active, not recruiting Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF;   Drug: COPE
15 Completed A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-6620;   Drug: GS-6620 tablet, 450 mg BID;   Drug: GS-6620 tablet
16 Completed Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: GS-9857;   Drug: Placebo to match GS-9857;   Drug: SOF/GS-5816
17 Recruiting Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India
Condition: Hepatitis C Virus
Intervention: Drug: SOF
18 Completed A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: Chronic Hepatitis C Infection
Interventions: Drug: GS-9190;   Drug: GS-9256;   Biological: Pegasys®;   Drug: Copegus®;   Drug: GS-9190 placebo;   Drug: GS-9256 placebo
19 Recruiting Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: Placebo
20 Recruiting Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.